Home
About Us
Scientific Platforms
- ADCs
- Publications
Team
News
Contact

Search

Search
- Search

Home
About Us
Scientific Platforms
- ADCs
- Publications
Team
News
Contact

Home » Uncategorized » Manhattan BioSolutions has been awarded Phase 1 SBIR Grant from the National Cancer Institute, National Institute Of Health

Uncategorized

Manhattan BioSolutions has been awarded Phase 1 SBIR Grant from the National Cancer Institute, National Institute Of Health

by Mbio2018|Published September 1, 2018

https://projectreporter.nih.gov/project_info_description.cfm?aid=9623199&icde=51409496&ddparam=&ddvalue=&ddsub=&cr=1&csb=default&cs=ASC&pball=

Project Number: 1R43CA228746-01A1

Title: NOVEL RECOMBINANT BCG FOR IMMUNOTHERAPY OF BLADDER CANCER

Manhattan BioSolutions Announces Grant Award from the New Jersey CSIT

Fort Lee, New Jersey Mar 10, 2022 (Issuewire.com) – Manhattan BioSolutions, an emerging biotechnology company focused on the development of innovative biologic therapies for […]

Published August 23, 2021

EVQLV and Manhattan BioSolutions Announce Grant Award from UB CAT

New York City, New York Jun 29, 2021 (Issuewire.com) – EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, […]

Published June 1, 2018

Manhattan BioSolutions has been awarded REACH grant from the New York State Center For Biotechnology at the Stony Brook University

Published May 8, 2025

Manhattan BioSolutions’ TxD ADC Collaboration Secures REACH Award from the New York Center for Biotechnology at the Stony Brook University

Previous post Manhattan BioSolutions has won prestigious Johnson & Johnson Innovation QuickFire Challenge Competition and award to receive free laboratory and office space at the newly open JLabs@NYC incubator in downtown Manhattan
Back to post list
Next post Manhattan BioSolutions establishes new laboratory space at the JLabs JNJ Innovation incubator in New York City